{"id":56500,"date":"2026-02-06T21:00:31","date_gmt":"2026-02-06T13:00:31","guid":{"rendered":"https:\/\/flcube.com\/?p=56500"},"modified":"2026-02-06T21:00:32","modified_gmt":"2026-02-06T13:00:32","slug":"keytruda-wins-20th-china-approval-for-endometrial-cancer-in-first-line-setting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56500","title":{"rendered":"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck &amp; Co.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE:\u202fMRK<\/a>) announced that <strong>Keytruda (pembrolizumab)<\/strong> has received its <strong>20th indication approval in China<\/strong>, becoming the <strong>first PD\u20111 inhibitor<\/strong> approved for first\u2011line treatment of <strong>mismatch repair\u2011deficient (dMMR) primary advanced or recurrent endometrial carcinoma<\/strong>. The approval expands Keytruda&#8217;s gynecologic cancer franchise in the world&#8217;s second\u2011largest pharmaceutical market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-clinical-data\">Regulatory Milestone &amp; Clinical Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Merck &amp; Co. (NYSE:\u202fMRK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Keytruda (pembrolizumab)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>dMMR primary advanced or recurrent endometrial carcinoma (first\u2011line)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>Carboplatin + paclitaxel, followed by pembrolizumab monotherapy maintenance<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>Phase\u202fIII KEYNOTE\u2011868 (NRG\u2011GY018) trial<\/td><\/tr><tr><td><strong>China Approvals<\/strong><\/td><td>20 total indications<\/td><\/tr><tr><td><strong>Strategic Significance<\/strong><\/td><td>First PD\u20111 inhibitor for first\u2011line endometrial cancer in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-keynote-868-trial-results\">KEYNOTE-868 Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cohort<\/th><th>Treatment Group<\/th><th>Median PFS<\/th><th>Control Group<\/th><th>Median PFS<\/th><th>Hazard Ratio<\/th><th>P\u2011Value<\/th><\/tr><\/thead><tbody><tr><td><strong>dMMR<\/strong><\/td><td>Keytruda + chemo<\/td><td>Not reached (95% CI: 30.7, NR)<\/td><td>Placebo + chemo<\/td><td>6.5 months (95% CI: 6.4, 8.7)<\/td><td>HR: 0.30 (0.19\u20130.48)<\/td><td>p&lt;0.0001<\/td><\/tr><tr><td><strong>pMMR<\/strong><\/td><td>Keytruda + chemo<\/td><td>11.1 months (95% CI: 8.7\u201313.5)<\/td><td>Placebo + chemo<\/td><td>8.5 months (95% CI: 7.2, 8.8)<\/td><td>HR: 0.60 (0.46\u20130.78)<\/td><td>p&lt;0.0001<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Gynecologic Cancer Market:<\/strong> Endometrial cancer affects <strong>~70,000<\/strong> new patients annually; dMMR subset represents <strong>25\u201330%<\/strong> of cases<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage:<\/strong> As first approved PD\u20111 inhibitor for this indication, Keytruda secures premium positioning before competitors (including domestic PD\u20111 inhibitors) enter market<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate <strong>\u00a5800\u202fmillion\u20131.2\u202fbillion<\/strong> (US$110\u2013170\u202fmillion) peak annual sales for this indication in China<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> 20th approval reinforces Keytruda&#8217;s dominance in China immuno\u2011oncology; supports continued NRDL listing negotiations<\/li>\n\n\n\n<li><strong>Global Alignment:<\/strong> Approval aligns with FDA and EMA approvals, enabling consistent global clinical practice<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Commercial launch expected <strong>Q2\u202f2026<\/strong>; physician education programs targeting gynecologic oncologists to commence immediately<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration, and revenue projections for Keytruda in China. Actual results may differ due to competitive dynamics, pricing negotiations, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co. (MSD, NYSE:\u202fMRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56501,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,2675,176,903,18,15],"class_list":["post-56500","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co. (MSD, NYSE:\u202fMRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval in China, becoming the first PD\u20111 inhibitor approved for first\u2011line treatment of mismatch repair\u2011deficient (dMMR) primary advanced or recurrent endometrial carcinoma. The approval expands Keytruda&#039;s gynecologic cancer franchise in the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56500\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co. (MSD, NYSE:\u202fMRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval in China, becoming the first PD\u20111 inhibitor approved for first\u2011line treatment of mismatch repair\u2011deficient (dMMR) primary advanced or recurrent endometrial carcinoma. The approval expands Keytruda&#039;s gynecologic cancer franchise in the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56500\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T13:00:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T13:00:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting\",\"datePublished\":\"2026-02-06T13:00:31+00:00\",\"dateModified\":\"2026-02-06T13:00:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500\"},\"wordCount\":319,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0601.webp\",\"keywords\":[\"Cancer\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56500#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56500\",\"name\":\"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0601.webp\",\"datePublished\":\"2026-02-06T13:00:31+00:00\",\"dateModified\":\"2026-02-06T13:00:32+00:00\",\"description\":\"Merck & Co. (MSD, NYSE:\u202fMRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval in China, becoming the first PD\u20111 inhibitor approved for first\u2011line treatment of mismatch repair\u2011deficient (dMMR) primary advanced or recurrent endometrial carcinoma. The approval expands Keytruda's gynecologic cancer franchise in the world's second\u2011largest pharmaceutical market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56500\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56500#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co. (MSD, NYSE:\u202fMRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval in China, becoming the first PD\u20111 inhibitor approved for first\u2011line treatment of mismatch repair\u2011deficient (dMMR) primary advanced or recurrent endometrial carcinoma. The approval expands Keytruda's gynecologic cancer franchise in the world's second\u2011largest pharmaceutical market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56500","og_locale":"en_US","og_type":"article","og_title":"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting","og_description":"Merck & Co. (MSD, NYSE:\u202fMRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval in China, becoming the first PD\u20111 inhibitor approved for first\u2011line treatment of mismatch repair\u2011deficient (dMMR) primary advanced or recurrent endometrial carcinoma. The approval expands Keytruda's gynecologic cancer franchise in the world's second\u2011largest pharmaceutical market.","og_url":"https:\/\/flcube.com\/?p=56500","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T13:00:31+00:00","article_modified_time":"2026-02-06T13:00:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56500#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56500"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting","datePublished":"2026-02-06T13:00:31+00:00","dateModified":"2026-02-06T13:00:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56500"},"wordCount":319,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56500#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0601.webp","keywords":["Cancer","Merck Sharp &amp; Dohme","MSD","NYSE: MRK","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56500#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56500","url":"https:\/\/flcube.com\/?p=56500","name":"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56500#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56500#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0601.webp","datePublished":"2026-02-06T13:00:31+00:00","dateModified":"2026-02-06T13:00:32+00:00","description":"Merck & Co. (MSD, NYSE:\u202fMRK) announced that Keytruda (pembrolizumab) has received its 20th indication approval in China, becoming the first PD\u20111 inhibitor approved for first\u2011line treatment of mismatch repair\u2011deficient (dMMR) primary advanced or recurrent endometrial carcinoma. The approval expands Keytruda's gynecologic cancer franchise in the world's second\u2011largest pharmaceutical market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56500#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56500"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56500#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0601.webp","width":1080,"height":608,"caption":"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56500#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56500"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56500\/revisions"}],"predecessor-version":[{"id":56502,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56500\/revisions\/56502"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56501"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}